2023
1217-P: Willingness to Deintensify in Patients with Type 2 Diabetes—The Diabetes and Aging Study
HAIDER S, PARKER M, HUANG E, GRANT R, MOFFET H, LAITEERAPONG N, LIU J, LIPSKA K, KARTER A. 1217-P: Willingness to Deintensify in Patients with Type 2 Diabetes—The Diabetes and Aging Study. Diabetes 2023, 72 DOI: 10.2337/db23-1217-p.Peer-Reviewed Original ResearchType 2 diabetesOlder patientsKaiser Permanente Northern CaliforniaDe-intensify treatmentDuration of diabetesGlucose-lowering medicationsNumber of medicationsProportion of patientsClinical guideline recommendationsHealth status factorsPoor health statusCross-sectional analysisInsulin useComplex regimensLess medicationGuideline recommendationsPatients' willingnessAbbVie Inc.Side effectsDiabetesPatient experiencePatientsHealth statusHypoglycemia historyMedicationsDevelopment and Validation of the Life Expectancy Estimator for Older Adults with Diabetes (LEAD): the Diabetes and Aging Study
Karter A, Parker M, Moffet H, Lipska K, Laiteerapong N, Grant R, Lee C, Huang E. Development and Validation of the Life Expectancy Estimator for Older Adults with Diabetes (LEAD): the Diabetes and Aging Study. Journal Of General Internal Medicine 2023, 38: 2860-2869. PMID: 37254010, PMCID: PMC10228886, DOI: 10.1007/s11606-023-08219-y.Peer-Reviewed Original ResearchOlder adultsLife expectancyKaiser Permanente Northern CaliforniaRisk score toolLimited life expectancyClinical trial inclusionMortality prediction modelElectronic health recordsOlder patientsPatient characteristicsRetrospective cohortTrial inclusionAdvanced careCancer screeningClinical trialsTreatment goalsDiabetesSurvival analysisSurvival curvesLife expectancy modelCohortVital signsAging StudyHealth recordsKey ResultsIn
2018
Does Initiation of Basal Insulin Analogs in Patients with Type 2 Diabetes Mellitus Confer Advantages over Neutral Protamine Hagedorn (NPH) for Severe Hypoglycemia and Glycemic Control?
LIPSKA K, PARKER M, MOFFET H, HUANG E, KARTER A. Does Initiation of Basal Insulin Analogs in Patients with Type 2 Diabetes Mellitus Confer Advantages over Neutral Protamine Hagedorn (NPH) for Severe Hypoglycemia and Glycemic Control? Diabetes 2018, 67 DOI: 10.2337/db18-1311-p.Peer-Reviewed Original ResearchNeutral protamine HagedornType 2 diabetesReal-world clinical practiceSevere hypoglycemiaGlycemic controlInsulin analoguesClinical practiceKaiser Permanente Northern CaliforniaDiabetes medication useInsulin analogue useBasal insulin analoguesClinical trial populationsType of insulinHealth plan coverageHazard ratioInsulin initiationNPH insulinPatient characteristicsBasal insulinHemoglobin A1cMedication useSulfonylurea treatmentTrial populationHypoglycemic eventsNocturnal hypoglycemia